Plain-English translation of NCT05675813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding targeted medications like selinexor and 5-Azacitidine (or duvelisib and 5-Azacitidine) to standard chemotherapy works better than chemotherapy alone for people newly diagnosed with peripheral T-cell lymphoma. Your treatment plan will be personalized based on the genetic makeup of your cancer cells, discovered through a genetic test done after your first round of chemotherapy.
Peripheral T-cell lymphoma is a rare and aggressive blood cancer with poor survival rates—most patients live only 3-5 years even with current treatments. This trial aims to see if this medication combination tailored to your specific cancer's genetics can help patients live longer and have better responses to treatment.
You likely qualify if…
You likely don't qualify if…
You will receive your first cycle of standard chemotherapy, then have a genetic test done on your cancer cells. Based on those results, you will either continue with standard chemotherapy alone or be randomly assigned to receive the standard chemotherapy plus one of the new targeted medication combinations for 5 more cycles. Each cycle lasts 21 days, and you will have regular check-ups, blood tests, and scans to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China